Antisense Oligonucleotides Complementary to Bax Transcripts Reduce the Susceptibility of B-cell Chronic Lymphocytic Leukaemia Cells to Apoptosis in a Bcl-2 Independent Manner
- 1 January 2002
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 43 (10) , 2003-2009
- https://doi.org/10.1080/1042819021000015961
Abstract
Our previous work demonstrated that antisense oligonucleotides complementary to Bcl-2 mRNA sequences were able to reduce Bcl-2 protein expression in B-cell chronic lymphocytic leukaemia (B-CLL) cells. Furthermore, the reduction in Bcl-2 expression led to an increase in apoptotic cell death that was associated with an increase in Bax expression. In this present study antisense oligonucleotides directed towards the Bax translation initiation sequence were employed to determine whether Bcl-2 and Bax protein expression were interdependent upon one another and whether Bcl-2 antisense-induced apoptosis was mediated through a p53-dependent cell death pathway. The antisense oligonucleotide down-regulated Bax protein expression between 23.7 and 68.8% in the 20 B-CLL samples tested and significantly inhibited apoptotic cell death when compared to controls (p = 0.0001). Furthermore, these changes were independent of Bcl-2 expression suggesting that the previously observed increase in Bax expression following exposure of B-CLL cells to Bcl-2 antisense oligonucleotides was probably caused by the induction of apoptosis rather than a rheostatic response to the reduction in Bcl-2 protein expression. This notion was substantiated by the fact that p21 expression was induced in Bcl-2 antisense-treated B-CLL cells, a finding consistent with p53 activation.Keywords
This publication has 15 references indexed in Scilit:
- Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistanceBritish Journal of Cancer, 1997
- Bcl-2 and Bax function independently to regulate cell deathNature Genetics, 1997
- REGULATION OF CLINICAL CHEMORESISTANCE BY bcl‐2 AND BAX ONCOPROTEINS IN B‐CELL CHRONIC LYMPHOCYTIC LEUKAEMIABritish Journal of Haematology, 1996
- Flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniquesCytometry, 1996
- Bcl-2,Bax andp53 expression in B-CLL in relation toin vitro survival and clinical progressionInternational Journal of Cancer, 1996
- Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 1995
- Tumor suppressor p53 is a direct transcriptional activator of the human bax geneCell, 1995
- Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell deathCell, 1993
- Regulation of bcl-2 Proto-Oncogene Expression During Normal Human Lymphocyte ProliferationScience, 1987
- A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysisCancer, 1981